SunTrust Banks Analysts Lift Earnings Estimates for Sarepta Therapeutics Inc. (SRPT)
Sarepta Therapeutics Inc. (NASDAQ:SRPT) – SunTrust Banks boosted their Q3 2016 earnings per share estimates for Sarepta Therapeutics in a research note issued on Monday. SunTrust Banks analyst E. Nash now expects that the brokerage will earn ($1.12) per share for the quarter, up from their previous estimate of ($1.28). SunTrust Banks has a “Reduce” rating and a $48.00 price target on the stock. SunTrust Banks also issued estimates for Sarepta Therapeutics’ Q4 2016 earnings at ($1.14) EPS, FY2016 earnings at ($4.87) EPS, FY2017 earnings at ($1.43) EPS, FY2018 earnings at ($0.26) EPS, FY2019 earnings at $0.56 EPS and FY2020 earnings at $0.91 EPS.
Several other equities research analysts have also recently weighed in on SRPT. Oppenheimer Holdings Inc. reaffirmed a “buy” rating and set a $60.00 price objective on shares of Sarepta Therapeutics in a research report on Sunday, July 17th. Piper Jaffray Cos. reaffirmed a “sell” rating and set a $6.00 price objective on shares of Sarepta Therapeutics in a research report on Saturday, June 4th. Robert W. Baird reaffirmed an “outperform” rating and set a $23.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, May 26th. Vetr cut shares of Sarepta Therapeutics from a “buy” rating to a “strong sell” rating and set a $17.28 price objective for the company. in a research report on Wednesday, June 8th. Finally, Janney Montgomery Scott reaffirmed a “hold” rating on shares of Sarepta Therapeutics in a research report on Thursday, May 26th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $51.01.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded up 0.68% on Wednesday, reaching $56.11. 5,095,164 shares of the company were exchanged. Sarepta Therapeutics has a 12 month low of $8.00 and a 12 month high of $58.87. The company’s market cap is $2.69 billion. The company’s 50-day moving average price is $28.17 and its 200 day moving average price is $21.37.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/suntrust-banks-analysts-lift-earnings-estimates-for-sarepta-therapeutics-inc-srpt.html
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.19) by $0.16. During the same quarter in the previous year, the business posted ($0.87) EPS.
Several institutional investors have recently modified their holdings of SRPT. Teacher Retirement System of Texas boosted its position in shares of Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock worth $115,000 after buying an additional 724 shares in the last quarter. Advisor Group Inc. purchased a new position in shares of Sarepta Therapeutics during the second quarter worth about $154,000. Quantitative Systematic Strategies LLC purchased a new position in shares of Sarepta Therapeutics during the second quarter worth about $211,000. First Allied Advisory Services Inc. boosted its position in shares of Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock worth $245,000 after buying an additional 800 shares in the last quarter. Finally, National Planning Corp boosted its position in shares of Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock worth $242,000 after buying an additional 275 shares in the last quarter. Institutional investors own 72.09% of the company’s stock.
In other news, CEO Edward M. Md Kaye sold 24,557 shares of the firm’s stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total transaction of $736,710.00. Following the completion of the sale, the chief executive officer now owns 76,983 shares of the company’s stock, valued at approximately $2,309,490. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 10.90% of the company’s stock.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.